401 related articles for article (PubMed ID: 17520104)
21. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Burger ME; Fachineto R; Alves A; Callegari L; Rocha JB
Brain Res; 2005 Jan; 1031(2):202-10. PubMed ID: 15649445
[TBL] [Abstract][Full Text] [Related]
22. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
Haleem DJ; Batool F; Khan NH; Kamil N; Ali O; Saify ZS; Haleem MA
Med Sci Monit; 2002 Sep; 8(9):BR354-61. PubMed ID: 12218936
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Dhingra D; Goswami S; Gahalain N
Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
[TBL] [Abstract][Full Text] [Related]
24. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Bachus SE; Yang E; McCloskey SS; Minton JN
Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
Datta S; Jamwal S; Deshmukh R; Kumar P
Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
[TBL] [Abstract][Full Text] [Related]
26. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
27. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.
Burger M; Fachinetto R; Calegari L; Paixão MW; Braga AL; Rocha JB
Brain Res Bull; 2004 Dec; 64(4):339-45. PubMed ID: 15561469
[TBL] [Abstract][Full Text] [Related]
28. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
29. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.
Shirakawa O; Tamminga CA
Exp Neurol; 1994 May; 127(1):62-9. PubMed ID: 8200438
[TBL] [Abstract][Full Text] [Related]
30. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
31. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats.
Fachinetto R; Burger ME; Wagner C; Wondracek DC; Brito VB; Nogueira CW; Ferreira J; Rocha JB
Pharmacol Biochem Behav; 2005 Jul; 81(3):585-92. PubMed ID: 15936064
[TBL] [Abstract][Full Text] [Related]
32. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
Shireen E; Naeem S; Inam QU; Haleem DJ
Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196
[TBL] [Abstract][Full Text] [Related]
33. U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):601-5. PubMed ID: 18193111
[TBL] [Abstract][Full Text] [Related]
34. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Naidu PS; Kulkarni SK
Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
[TBL] [Abstract][Full Text] [Related]
35. B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Macêdo DS; Oliveira GV; Gomes PX; Araújo FY; Souza CM; Vasconcelos SM; Viana GS; Sousa FC; Carvalho AF
Behav Pharmacol; 2011 Oct; 22(7):674-80. PubMed ID: 21918383
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
37. Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
Patil R; Hiray Y; Shinde S; Langade P
Pharm Biol; 2012 Jun; 50(6):691-7. PubMed ID: 22136413
[TBL] [Abstract][Full Text] [Related]
38. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 May; 420(2-3):113-7. PubMed ID: 11408032
[TBL] [Abstract][Full Text] [Related]
39. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
40. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Singh A; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
